Nanobody CD5-CAR T cells for T-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of T-cell cancer that has come back or not responded to standard treatments, and no other curative options are available.
- You should be between 1 and 70 years old.
- Your cancer cells must have a specific marker called CD5 (detected by a lab test).
- You must be well enough to perform daily activities (ECOG score 0-2) and have a life expectancy of at least 60 days.
- If you receive cells from a donor, you must have a matched stem cell donor ready and be willing to consider a stem cell transplant if your cancer goes into remission.
- You must not have serious infections, heart or lung problems, other cancers, or uncontrolled diabetes. Women cannot be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Hear when a new Acute Lymphoblastic Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.